PROVEN TREATMENT FOR BLADDER AND  BOWEL CONTROL

Sacral neuromodulation (SNM) is a proven treatment option for bladder control and bowel control. Hundreds of thousands of patients worldwide have received SNM for bladder control and bowel control delivered by the InterStim™ system.

VIEW PRODUCTS
Medtronic Smart Programmer device for bladder and bowel control
Female physician discussing neuromodulation therapies with patient.

HOW THE INTERSTIM SYSTEM WORKS

With the InterStim™ system, the implanted neurostimulator and lead electrically stimulate the sacral nerve. This is thought to normalize neural communication between the bladder and brain1 and between the bowel and brain.2 Unlike oral medications that target the muscular component of bladder control, the InterStim system offers control of symptoms through direct modulation of the nerve activity.1 , 2

One key advantage of this therapy is that it can be tested for potential success prior to implantation. The evaluation provides an opportunity to find out whether adequate symptom reduction is achieved in as few as three to seven days. Complications can occur with the evaluation, including tissue damage, infection, and technical problems with the device. Patients should be instructed on operating the programmer and given precautions related to the evaluation.

InterStim II neurostimulator implanted parallel to the sacral nerve.

FOR BLADDER CONTROL

  • Not all patients with bladder control problems benefit from standard medical therapy3,4
  • Standard pharmacological therapy for OAB consists of anticholinergics or β3- adrenoreceptor agonists, which are not effective for everyone5
  • More than 70% of patients stop taking OAB medications within six months due to side effects and/or lack of efficacy3
  • The InterStim system can provide effective bladder control and proven efficacy for patients who do not find relief from initial treatments6,7

 

FOR BOWEL CONTROL

  • Not all patients with bowel control problems benefit from medication, diet modification, and exercise8
  • The InterStim system offers a minimally invasive option that can restore bowel function*
  • The InterStim system is effective, safe, and may offer patients improved quality of life9

 

SHOW PATIENTS THE WAY

The Care Pathway helps patients envision their journey to relief, so they know what to expect and can keep moving forward.

View Care Pathway Tools
Females outside discussing the Medtronic care pathway for urinary retention.

UNDERSTAND THE INDICATIONS

Learn the parameters of patient selection for bladder control and bowel control.

VIEW TOOLS
Bullseye representing Medtronic’s next level sacral neuromodulation systems.

REACH THE NEXT LEVEL

Discover resources and support practices you can use to improve efficiency and find opportunities for growth.

EMPOWER YOUR PRACTICE
Doctor speaking with female neuromodulation therapy patient

EXPLORE PROGRAMMING

Download resources to guide programming decisions for the InterStim™ system.

DOWNLOAD RESOURCES

STREAMLINE REIMBURSEMENT

Find details required to promote smooth prior authorization and reimbursement.

VIEW DETAILS

PURSUE ONLINE EDUCATION

Take convenient courses specifically designed for clinicians treating patients with OAB, non-obstructive urinary retention and chronic fecal incontinence.

SEE COURSES
*

Restored bladder function defined as ≥50% reduction in dysfunctional voiding symptoms from baseline. Restored bowel function is defined as ≥50% reduction in chronic fecal incontinence episodes.

Data from InterStim Sales Analysis. Medtronic, Inc. October 2016.

1

Leng WW, Chancellor MB. How sacral nerve stimulation neuromodulation works. Urol Clin North Am. 2005;32:11-18.

2

Patton V, Wiklendt L, Arkwright JW, Lubowski DZ, Dinning PG. The effect of sacral nerve stimulation on distal colonic motility in patients with fecal incontinence. Br J Surg. 2013;100:959–968.

3

Yeaw J, Benner J, Walt JG et al. Comparing adherence and persistence across 6 chronic medication classes. J Manag Care Pharm. 2009:15(9):724-736.

4

Haab F, Castro-Diaz D. Persistence with antimuscarinic therapy in patients with overactive bladder. Int J Clin Pract. 2005;59(8):931-937.

5

Gormley EA, Lightner DJ, Burgio KL, et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline. American Urological Association (AUA). J Urol. 2015 May;193(5):1572-80.

6

Noblett K, Siegel S, Mangel J et al. Results of a prospective, multicenter study evaluating quality of life, safety, and efficacy of sacral neuromodulation at 12 months in subjects with symptoms of OAB. Neurourol Urodyn. 2014. doi:10.1002/nau.22707.

7

Medtronic InterStim Therapy Clinical Summary, 2018.

8

Wald A, Bharucha AE, Cosman BC, et al. ACG clinical guideline: management of benign anorectal disorders. Am J Gastroenterol. 2014 Aug;109(8):1141-1157.

9

Hull T, Giese C, Wexner SD, Mellgren A, Devroede G, et al. Long-term durability of sacral nerve stimulation therapy for chronic fecal incontinence. Dis Colon Rectum. 2013;56:234–245.